Wedbush Reaffirms Outperform Rating for Revolution Medicines (NASDAQ:RVMD)
Wedbush reaffirmed their outperform rating on shares of Revolution Medicines (NASDAQ:RVMD – Free Report) in a research report report published on Monday,Benzinga reports. They currently have a $67.00 target price on the stock. Other equities analysts have also issued research reports about the stock. UBS Group lifted their price target on shares of Revolution Medicines […]
Wedbush reaffirmed their outperform rating on shares of Revolution Medicines (NASDAQ:RVMD – Free Report) in a research report report published on Monday,Benzinga reports. They currently have a $67.00 target price on the stock. Other equities analysts have also issued research reports about the stock. UBS Group lifted their price target on shares of Revolution Medicines […]
